Newsroom - Page 11

Researchers in Germany have discovered that mitoxantrone—used to treat aggressive, relapsing, or progressive multiple sclerosis—can increase the risk of leukemia and colorectal cancer in those being treated.
Regeneron's CEO said ICER's methodology wasn't scientific. The nonprofit said analysis of a drug based on what people can afford to pay is the point of its work.
As CDC reports a record number of deaths from hepatitis C, it seeks to raise awareness of the need for screening and treatment. Authors and the editor of a special issue of The American Journal of Managed Care will take part in a briefing on the issue.
What we're reading, May 13, 2016: federal judge rules against Obamacare; Senate reaches deal for $1.1 billion to fight Zika; and Los Angeles is using healthcare funds to house the homeless.
Nonadherence to medications is a universal issue that has garnered significant attention in recent years. However, a new study concluded that medication nonadherence represents only a fraction of medication-related problems experience by patients.
The immunotherapy agent nivolumab was approved by the European Commission in combination with ipilimumab for the treatment of advanced melanoma, but rejected by the National Institute for Health and Care Excellence for use in patients with advanced lung cancer.
Cancer patients who receive a particular type of chemotherapy, called doxorubicin, run a risk of sustaining severe, lasting heart damage. But until now, there was no way of knowing who would experience this serious side effect.
In a blogpost on Health Affairs, 2 economists have challenged the claim made by researchers that packaging expensive, patented chemotherapy drugs into multiple vial sizes could reduce wastage and in turn significantly reduce healthcare costs.
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
HF Compendium
HF Compendium